Sales of Novo Nordisk's blockbuster Wegovy obesity drug rose 67% in the second quarter despite continued competition from compounded drug makers. The pharma giant last week cut its full-year ...

Novo Nordisk announced today that the FDA has approved Levemir for a pregnancy Category B classification, indicating that Levemir,, when used in pregnant women with diabetes, did not increase the ...

He has experience leading international operations, but not in the U.S., where Novo Nordisk’s biggest competitive threats lie, including rival Eli Lilly, which has a more effective drug in Zepbound.

Novo Nordisk, maker of the popular weight-loss drug Wegovy, says it has started to increase the availability of the drug for people in the U.S.

Compounding pharmacies are crimping sales of Novo Nordisk's obesity drug Wegovy by making what are essentially copies of the name-brand medicine. The company says it trying to stop them.

Novo Nordisk on Tuesday said it will offer its weight loss drug Wegovy through telehealth providers Hims & Hers Health, Ro and LifeMD to expand access to the blockbuster treatment now that it is ...

Novo Nordisk also created semaglutide.com, a resource for patients to learn about the dangers of compounded and counterfeit products, as well as how to access authentic, FDA-approved treatments.

Novo Nordisk says its drug Levemir gets new approval for small children with type 1 diabetes Story by Associated Press May 22, 2012 at 2:31 PM UTC ...

Novo Nordisk's shares plunged more than 20% Tuesday, after the company cut the forecast for its flagship obesity drug. Before the markets opened, the company announced that sales of its obesity ...

Novo Nordisk also created semaglutide.com, a resource for patients to learn about the dangers of compounded and counterfeit products, as well as how to access authentic, FDA-approved treatments.